Importance of Managing Nausea Related to T-DXd in HR+ Breast Cancer
January 7th 2024Sarah Donahue, MPH, NP, discusses her strategy for administering doxorubicin, cyclophosphamide, and antiemetics to manage nausea following trastuzumab deruxtecan therapy for patients with hormone receptor–positive breast cancer.